23:26 , Dec 17, 2018 |  BC Extra  |  Company News

Novo gets option to cardiovascular company Staten

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) received an option to acquire Staten Biotechnology B.V. (Nijmegen, the Netherlands) along with its lead candidate, STT-5058, which is in development to reduce cardiovascular risk in patients with hypertriglyceridemia....
18:55 , Mar 17, 2017 |  BC Week In Review  |  Company News

argenx, Staten Biotechnology deal

Staten exercised an option under a 2015 deal to license ARGX-116 from argenx. Staten is responsible for ongoing development of the preclinical dyslipidemia candidate, and argenx is eligible for a "double-digit portion on income related...